International Stem Cell (ISCO) Liabilities and Shareholders Equity (2010 - 2026)
International Stem Cell (ISCO) posted quarterly Liabilities and Shareholders Equity of $4.8 million for Q4 2025, down 6.84% year-over-year from $5.2 million in Q4 2024, and down 8.77% quarter-over-quarter from $5.3 million in Q3 2025.
International Stem Cell (ISCO) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
International Stem Cell (ISCO) has reported Liabilities and Shareholders Equity for 16 consecutive years, with $4.8 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 6.84% year-over-year to $4.8 million; the TTM figure through Dec 2025 stood at $21.3 million (changed 0.21% YoY), while the FY2025 annual figure was $4.8 million, down 6.84% from the prior year.
- Liabilities and Shareholders Equity retreated to $4.8 million in Q4 2025 per ISCO's latest filing, from $5.3 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $6.0 million in Q1 2021 and bottomed at $4.8 million in Q4 2025.
- Historically, Liabilities and Shareholders Equity has averaged $5.4 million across 5 years, with a median of $5.4 million in 2023.
- Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity slipped 17.28% — and 2023, when it climbed 11.88%.
- International Stem Cell's Liabilities and Shareholders Equity stood at $4.9 million in 2021, then increased by 3.82% to $5.1 million in 2022, then rose by 4.97% to $5.4 million in 2023, then retreated by 4.03% to $5.2 million in 2024, then retreated by 6.84% to $4.8 million in 2025.
- Business Quant data shows ISCO's Liabilities and Shareholders Equity at $4.8 million in Q4 2025, $5.3 million in Q3 2025, and $5.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | International Stem Cell | 3.76 Mn | 2.67 Mn | 1.46 Mn | 5.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.06 Mn |
| Dec 31, 2025 | 4.82 Mn |
| Sep 30, 2025 | 5.28 Mn |
| Jun 30, 2025 | 5.55 Mn |
| Mar 31, 2025 | 5.62 Mn |
| Dec 31, 2024 | 5.17 Mn |
| Sep 30, 2024 | 5.18 Mn |
| Jun 30, 2024 | 5.59 Mn |
| Mar 31, 2024 | 5.37 Mn |
| Dec 31, 2023 | 5.39 Mn |
| Sep 30, 2023 | 5.64 Mn |
| Jun 30, 2023 | 5.79 Mn |
| Mar 31, 2023 | 5.34 Mn |
| Dec 31, 2022 | 5.14 Mn |
| Sep 30, 2022 | 5.04 Mn |
| Jun 30, 2022 | 5.42 Mn |
| Mar 31, 2022 | 5.50 Mn |
| Dec 31, 2021 | 4.95 Mn |
| Sep 30, 2021 | 4.94 Mn |
| Jun 30, 2021 | 5.61 Mn |